Ask HopeStage to review this study with me
Study ID: NCT05227703. We help you review the study, but cannot decide medical eligibility.
CompletedNCT05227703
Safety study of Emraclidine 15 mg in schizophrenia
This study is completed in the United States, in Bulgaria, and in Hungary. It is testing Emraclidine 15 mg for schizophrenia.
SchizophreniaDrugFrom 18 Years to 65 Years
The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.
Check recruitment and locations
Recruitment checked against the registry by HopeStage on . Registry information can change. Always confirm availability with the research team.
The overall study status can differ from each site's status. Open a country to see its locations and their registry status.
Bulgaria · 4 sites
- Sofia, Sofia-GradSofia, Sofia-GradSite status: Not listed — confirm with the team
- Burgas, BurgasBurgasSite status: Not listed — confirm with the team
- Pleven, PlevenPlevenSite status: Not listed — confirm with the team
- Sofia, SofiaSofiaSite status: Not listed — confirm with the team
Hungary · 3 sites
- Kalocsa, Bács-KiskunKalocsa, Bács-Kiskun countySite status: Not listed — confirm with the team
- Győr, Győr-Moson-SopronGyőr, Győr-Moson-SopronSite status: Not listed — confirm with the team
- Budapest, BudapestBudapestSite status: Not listed — confirm with the team
United States · 19 sites
- Bentonville, ArkansasBentonville, ArkansasSite status: Not listed — confirm with the team
- Bellflower, CaliforniaBellflower, CaliforniaSite status: Not listed — confirm with the team
- La Habra, CaliforniaLa Habra, CaliforniaSite status: Not listed — confirm with the team
- San Diego, CaliforniaSan Diego, CaliforniaSite status: Not listed — confirm with the team
- Sherman Oaks, CaliforniaSherman Oaks, CaliforniaSite status: Not listed — confirm with the team
- Torrance, CaliforniaTorrance, CaliforniaSite status: Not listed — confirm with the team
- New Haven, ConnecticutNew Haven, ConnecticutSite status: Not listed — confirm with the team
- Homestead, FloridaHomestead, FloridaSite status: Not listed — confirm with the team
- Miami, FloridaMiami, FloridaSite status: Not listed — confirm with the team
- Miami Lakes, FloridaMiami Lakes, FloridaSite status: Not listed — confirm with the team
- Miami Springs, FloridaMiami Springs, FloridaSite status: Not listed — confirm with the team
- Atlanta, GeorgiaAtlanta, GeorgiaSite status: Not listed — confirm with the team
- Savannah, GeorgiaSavannah, GeorgiaSite status: Not listed — confirm with the team
- Chicago, IllinoisChicago, IllinoisSite status: Not listed — confirm with the team
- Chicago, IllinoisChicago, IllinoisSite status: Not listed — confirm with the team
- Berlin, New JerseyBerlin, New JerseySite status: Not listed — confirm with the team
- Marlton, New JerseyMarlton, New JerseySite status: Not listed — confirm with the team
- Charlotte, North CarolinaCharlotte, North CarolinaSite status: Not listed — confirm with the team
- Austin, TexasAustin, TexasSite status: Not listed — confirm with the team
Key information made simple
What is this study testing?
This study is testing whether Emraclidine 15 mg may be useful for adults experiencing schizophrenia.
What would participation involve?
Participants may receive Emraclidine 15 mg, attend study visits with the research team. The protocol may also involve randomization, placebo, or a comparison group. The registry lists locations in Bulgaria, in Hungary, and in the United States.
Who is it mainly for?
This study appears to be mainly for adults with schizophrenia.
What should you check before joining?
Ask about the dose, safety monitoring, and possible side effects, whether there is placebo, randomization, or a comparison group, how many visits or travel steps are needed, the exact eligibility criteria.
Your next step
Study sites are listed in the registry. Recruitment status can differ between sites. Ask the research team to confirm the location, any in-person visits, time commitment, costs or compensation, and participation criteria.
Questions to ask before joining
- What are the exact eligibility criteria, and what could exclude someone?
- How many visits, assessments, or follow-ups are expected, and over what period?
- What risks, side effects, practical burdens, or alternatives should be understood first?
- Who should be contacted to confirm locations, timing, compensation, and next steps?
Things to check before joining
Study start dateStarted: July 5, 2022
- Recruitment status
- Completed
- Enrollment listed in the registry
- 391
- Sponsor
- AbbVie
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States, Bulgaria, Hungary
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT05227703
- Official title
- A Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Two Fixed Doses (15 mg and 30 mg QD) of CVL-231 (Emraclidine) in Participants With Schizophrenia Experiencing an Acute Exacerbation of Psychosis
- Official source
- Official registry link
Want help reviewing this study?
Study ID: NCT05227703. We help you review the study, but cannot decide medical eligibility.
For you
Participation may contribute to research. Personal benefit is not guaranteed.
Ask the research team to explain the activities, time commitment, and follow-up involved.
Study sites are listed. Confirm the relevant site and any travel before making plans.
Not medical advice
Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com
Questions about this study
What is this study trying to understand?
This study is exploring medication or study treatment for people with schizophrenia. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.
Does this study involve a medication?
This appears to be a medication / drug study involving Emraclidine 15 mg, Emraclidine 30 mg, Placebo. Phase 2 studies usually explore whether the intervention may work, while continuing to monitor safety.
Who might this study be for?
This study may concern people with schizophrenia; age range: From 18 Years to 65 Years. The criteria appear fairly specific, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.
What would I likely need to do?
You may need to take a study treatment and have regular medical follow-up. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.
What side effects, interactions, or treatment changes should I check?
If the study involves a medication, ask whether it is already approved, experimental, or being tested for a new use. Check possible side effects, interactions with current treatment, dose changes, monitoring, and what happens if you feel worse. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.
Will I need to travel or attend in-person visits?
The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.
Who is behind this study?
This study is sponsored by AbbVie, which appears to be unknown or unclear. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.
Can I still join this study?
The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meExplore related studies
Other studies that may be relevant based on condition, country, or study type.
CompletedNCT01157351
15 Month Study for Adults Who Have Been Diagnosed With Schizophrenia and Incarcerated
This study is completed. It focuses on schizophrenia and currently lists study information in the United States.
CompletedEUCTR 2008-002247-16
A 24-month, Prospective, Randomized, Active-Controlled, Open-Label, Rater Blinded, Multicenter, International Study of the Prevention of Relapse Comparing Long-Acting Injectable Paliperidone Palmit...
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
CompletedNCT01714713
EVP-6124 (Alpha-7 nAChR) for schizophrenia
This study is completed in the United States, in Australia, in Canada, .... It is testing EVP-6124 (Alpha-7 nAChR) for schizophrenia.